A long-rumored spin-off proposing the creation of the “number one standalone European generics company and a global leader in generics and biosimilars,” an acquisition valued at more than $3bn in the burgeoning biosimilars sector, and a landmark special purpose acquisition company (SPAC) merger delivering a much-desired public listing – 2022 proved another busy year for dealmaking.
In a year dogged by geopolitical turmoil, plunging stock and rising energy prices, as well as supply chain issues, industry...
